Table 1. Levels of free docosahexaenoic acid (nmol/g) and docosahexaenoate-containing phosphatidylethanolamine (nmol/g) in various brain regions of control subjects and subjects with Alzheimer's disease.

	Control subjects	Subjects with Alzheimer's disease	Adjusted Difference	P-value*
	Mean ± SD ; N	Mean ± SD ; N	(95% CI)
DHA
Temporal cortex	123.61±24.07 ; 17	102.29±40.66 ; 36	−23.87 ( −45.18, −2.57 )	0.029
Frontal cortex	119.99±50.8 ; 17	97.45±26.19 ; 37	−22.11 ( −42.37, −1.85 )	0.033
Cerebellum	218.18±101.66 ; 16	174.86±45.22 ; 35	−42.58 ( −83.31, −1.84 )	0.041
Pooled	152.64±79.12 ; 17	124.35±51.72 ; 37	−28.87 ( −49.81, −7.94 )	0.007
Phosphatidylethanolamine**
Temporal cortex	11.52±3.58 ; 17	8.26±4.06 ; 36	−3.22 ( −5.56, −0.88 )	0.008
Frontal cortex	29.7±5.94 ; 17	23.83±5.84 ; 37	−5.82 ( −9.32, −2.32 )	0.002
Cerebellum	13.71±4.16 ; 16	10.37±4.75 ; 35	−3.44 ( −6.28, −0.61 )	0.018
Pooled	18.4±9.43 ; 17	14.32±8.6 ; 38	−4.14 ( −7.2, −1.09 )	0.008

Abbreviations: CI, confidence interval.

*P-values for differences between means were computed by linear regression analysis for each fatty acid in selected brain regions and Generalized Estimating Equations for the pooled analysis in the entire brain after adjustment for age, gender, and post mortem interval.

**Phosphatidylethanolamine was 1-stearoyl, 2-docosahexaenoyl-sn-glycero-phosphoethanolamine.